Liezl Schonken, a Safety Physician at Panacea, discusses pharmacogenomics and how it may be implemented to prevent adverse drug reactions.
Read MoreMichelle Patton discusses her experiences of being an EU QPPV at Panacea.
Read MoreMartika Taylor, a Senior Safety Scientist at Panacea, looks at the use of Developmental Risk Management Plans (DRMPs) in Pharmacovigilance.
Read MorePart Two looks at PV specifics and also Quality, Non-clinical and Clinical issues and their interconnection with safety.
Read MoreLudmila Curi, a Panacea EU QPPV and Safety Physician, looks at the PV considerations for Biological and Biosimilar medicines in the EU.
Read MorePanacea’s Michaela Muller talks about her experiences moving from nursing to a career in pharmacovigilance.
Read MoreAn alternative to the traditional in-house PV model is the outsourcing of PV work to a specialist company. Outsourcing is a solution that allows the delegation of the PV responsibilities to specialist service providers.
Read MoreDue to the high number of audits required, it is essential that Marketing Authorisation Holders (MAH) and their service providers are well prepared.
Read MoreGlobal harmonisation of PV is a work in progress, something we all need to pay attention to, whether we are a leading think tank or a small PV service provider.
Read MoreA PVA is a written agreement between the MAH and a third party which outlines the responsibilities of each party with regards to pharmacovigilance.
Read More